Pre-made Carotuximab benchmark antibody ( Whole mAb, anti-ENG therapeutic antibody, Anti-END/HHT1/ORW1 Antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Carotuximab biosimilar, Whole mAb, Anti-ENG Antibody: Anti-END/HHT1/ORW1 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Carotuximab (INN) (TRC-105) is a chimeric monoclonal antibody designed for the treatment of cancer.
| Products Name (INN Index) | Pre-Made Carotuximab biosimilar, Whole mAb, Anti-ENG Antibody: Anti-END/HHT1/ORW1 therapeutic antibody |
|---|---|
| INN Name | Carotuximab |
| Target | ENG |
| Format | Whole mAb |
| Derivation | Chimeric (Mouse/Human) |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Discontinued |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2015 |
| Year Recommended | 2016 |
| Companies | National Cancer Institute (USA),Santen Pharmaceutical,TRACON Pharmaceuticals,University of Alabama at Birmingham,University of Minnesota,Roswell Park Cancer Institute |
| Conditions Approved | NA |
| Conditions Active | NA |
| Conditions Discontinued | Fallopian tube cancer,Ovarian cancer,Peritoneal cancer,Prostate cancer,Haemangiosarcoma,Choriocarcinoma,Glioblastoma,Liver cancer,Renal cell carcinoma,Soft tissue sarcoma,Breast cancer,Non-small cell |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | ENG |
| Package |
